Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...

Novo Nordisk, Eli Lilly, and others are advancing obesity drugs, with key data expected for assets including CagriSema, ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...

AstraZeneca is looking to increase its presence north of the US border. The UK pharma said it is budgeting $570 million to ...

Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Teva, Astellas and AstraZeneca say they will participate in the next round of Medicare negotiations under the Inflation ...

Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.